Baumer Yvonne, Irei Jason, Boisvert William A
Social Determinants of Obesity and Cardiovascular Risk Laboratory, NIH, NHLBI, Bethesda, MD, USA.
Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
Nat Rev Cardiol. 2025 May;22(5):315-332. doi: 10.1038/s41569-024-01100-3. Epub 2024 Nov 18.
The presence of cholesterol crystals (CCs) in tissues was first described more than 100 years ago. CCs have a pathogenic role in various cardiovascular diseases, including myocardial infarction, aortic aneurysm and, most prominently, atherosclerosis. Although the underlying mechanisms and signalling pathways involved in CC formation are incompletely understood, numerous studies have highlighted the existence of CCs at various stages of atheroma progression. In this Review, we summarize the mechanisms underlying CC formation and the role of CCs in cardiovascular disease. In particular, we explore the established links between lipid metabolism across various cell types and the formation of CCs, with a focus on CC occurrence in the vasculature. We also discuss CC-induced inflammation as one of the pathogenic features of CCs in the atheroma. Finally, we summarize the therapeutic strategies aimed at reducing CC-mediated atherosclerotic burden, including approaches to inhibit CC formation in the vasculature or to mitigate the inflammatory response triggered by CCs. Addressing CC formation might emerge as a crucial component in our broader efforts to combat cardiovascular disease.
组织中胆固醇晶体(CCs)的存在早在100多年前就被首次描述。CCs在各种心血管疾病中具有致病作用,包括心肌梗死、主动脉瘤,最显著的是动脉粥样硬化。尽管CC形成所涉及的潜在机制和信号通路尚未完全了解,但大量研究强调了CCs在动脉粥样硬化进展的各个阶段都存在。在本综述中,我们总结了CC形成的潜在机制以及CCs在心血管疾病中的作用。特别是,我们探讨了不同细胞类型的脂质代谢与CC形成之间已确立的联系,重点关注血管中CC的出现。我们还讨论了CC诱导的炎症作为动脉粥样硬化中CCs的致病特征之一。最后,我们总结了旨在减轻CC介导的动脉粥样硬化负担的治疗策略,包括抑制血管中CC形成或减轻CCs引发的炎症反应的方法。解决CC形成问题可能会成为我们抗击心血管疾病更广泛努力中的关键组成部分。